Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$332 Mln
Revenue (TTM)
$7 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.5
Industry P/E
--
EV/EBITDA
-0.7
Div. Yield
0 %
Debt to Equity
0.1
Book Value
$1.6
EPS
$-0.2
Face value
--
Shares outstanding
151,028,955
CFO
$-185.65 Mln
EBITDA
$-283.06 Mln
Net Profit
$-273.71 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ovid Therapeutics (OVID)
| 35.0 | 35.0 | 35.0 | 610.4 | -5.2 | -11.6 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ovid Therapeutics (OVID)
| 74.6 | -70.7 | 73.1 | -42.1 | 39.0 | -44.3 | 71.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ovid Therapeutics (OVID)
|
2.2 | 332.3 | 7.3 | -17.4 | -580.8 | -17.5 | -- | 2.5 |
| 61.0 | 8,546.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.1 | 15.0 | |
| 229.3 | 14,074.4 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 8,218.7 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 43.9 | 11,764.8 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 93.8 | 12,307.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 60.9 | |
| 546.9 | 12,545.6 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 498.3 | 14,143.5 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.7 | 30.2 | |
| 105.4 | 8,288.6 | 0.0 | -425.4 | -- | -36.7 | -- | 6.7 | |
| 310.4 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a... GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. Read more
President, CEO & Chairman
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
President, CEO & Chairman
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ovid Therapeutics Inc (OVID) is $2.20 (NASDAQ) as of 02-Apr-2026 16:57 EDT. Ovid Therapeutics Inc (OVID) has given a return of -5.17% in the last 3 years.
Since, TTM earnings of Ovid Therapeutics Inc (OVID) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-7.64
|
1.02
|
|
2024
|
-2.51
|
0.97
|
|
2023
|
-4.35
|
2.59
|
|
2022
|
-2.55
|
0.99
|
|
2021
|
1.78
|
1.22
|
The 52-week high and low of Ovid Therapeutics Inc (OVID) are Rs 2.72 and Rs 0.24 as of 05-Apr-2026.
Ovid Therapeutics Inc (OVID) has a market capitalisation of $ 332 Mln as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ovid Therapeutics Inc (OVID), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.04
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.